Stock RPTX REPARE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.2 USD 0.00% Intraday chart for Repare Therapeutics Inc. -4.76% -56.16%
Apr. 26 Repare Therapeutics Inc. Announces Directorate Changes CI
Feb. 28 Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Repare Therapeutics Inc. Announces Directorate Changes
CI
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
BU
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
BU
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
BU
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
CI
HC Wainwright Adjusts Repare Therapeutics Price Target to $10 From $25, Maintains Buy Rating
MT
Repare Therapeutics to Regain Global Rights to Oncology Therapy Camonsertib After Termination of Collaboration With Roche
MT
Repare Therapeutics to Regain Global Rights to Camonsertib
BU
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
BU
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RPTX Stock
  4. News Repare Therapeutics Inc.